Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma
- 30 January 2024
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (5) , 949-954
Abstract
Background and Aim: While several predictive models for the development of hepatocellular carcinoma (HCC) have been proposed, including those for patients with chronic hepatitis C virus (HCV) infection who have achieved sustained virologic response (SVR), the best model may differ between regions. We compared the ability of six reported models to stratify the risk of post‐SVR HCC in Japan, where rigorous surveillance and early detection of HCC is common.Methods: A total of 6048 patients with no history of HCC who achieved SVR by oral direct‐acting antiviral drugs were enrolled in this nationwide study. Patients continued HCC surveillance every 6 months after SVR. The incidence of post‐SVR HCC was compared between risk groups using the aMAP score, FIB‐4 index, Tahata model, GAF4 criteria, GES score, and ADRES score.Results: During the observation period with a median duration of 4.0 years after SVR, post‐SVR HCC developed in 332 patients (5.5%). All six models performed significantly at stratifying the incidence of HCC. However, Harrell's C‐index was below 0.8 for all models (range, 0.660–0.748), indicating insufficient stratification ability.Conclusion: Although all six proposed models demonstrated a good ability to predict the development of post‐SVR HCC, their ability to stratify the risk of post‐SVRHCC was unsatisfactory. Further studies are necessary to identify the best model for assessing the risk of post‐SVR HCC in regions where early detection of HCC is common.Keywords
This publication has 18 references indexed in Scilit:
- Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 updateHepatology Research, 2019
- Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysisJournal of Gastroenterology and Hepatology, 2018
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral AgentsGastroenterology, 2017
- Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1BJournal of Hepatology, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon‐free versus interferon‐based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in JapanJournal of Viral Hepatitis, 2016
- Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study fromJapanHepatology Research, 2015
- Impact of Surveillance on Survival of Patients With Initial Hepatocellular Carcinoma: A Study From JapanClinical Gastroenterology and Hepatology, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006